These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12547599)

  • 1. Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16.
    Bubeník J; Mikysková R; Vonka V; Mendoza L; Símová J; Smahel M; Indrová M
    Vaccine; 2003 Feb; 21(9-10):891-6. PubMed ID: 12547599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases.
    Mikysková R; Bubenik J; Mendoza L; Vonka V; Smahel M; Símová J; Jandlová T
    Clin Exp Metastasis; 2000; 18(7):581-7. PubMed ID: 11688963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
    Bubeník J; Símová J; Hájková R; Sobota V; Jandlová T; Smahel M; Sobotková E; Vonka V
    Int J Oncol; 1999 Mar; 14(3):593-7. PubMed ID: 10024696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
    Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
    Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
    Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
    Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
    Indrová M; Bubeník J; Mikysková R; Vonka V; Smahel M; Zák R; Símová J; Bieblová J; Mendoza L; Jandlová T
    Int J Oncol; 2002 Mar; 20(3):643-6. PubMed ID: 11836582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local IFN-gamma therapy of HPV16-associated tumours.
    Mikysková R; Bieblová J; Símová J; Indrová M; Jandlová T; Vonka V; Smahel M; Bubeník J; Mendoza L
    Folia Biol (Praha); 2003; 49(1):26-32. PubMed ID: 12630665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours.
    Mendoza L; Bubeník J; Símová J; Jandlová T; Vonka V; Mikysková R
    Int J Oncol; 2003 Jul; 23(1):243-7. PubMed ID: 12792800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-based vaccines for therapy of HPV16-induced tumours.
    Bubeník J; Símová J; Vonka V; Smahel M; Mikysková R; Mendoza L
    Adv Exp Med Biol; 2001; 495():359-63. PubMed ID: 11774593
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.
    Indrová M; Bubeník J; Símová J; Vonka V; Nemecková S; Mendoza L; Reinis M
    Int J Mol Med; 2001 Jan; 7(1):97-100. PubMed ID: 11115616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
    Chandy AG; Nurkkala M; Josefsson A; Eriksson K
    Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
    Gérard CM; Baudson N; Kraemer K; Bruck C; Garçon N; Paterson Y; Pan ZK; Pardoll D
    Vaccine; 2001 Mar; 19(17-19):2583-9. PubMed ID: 11257396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-inhibitory effects of dendritic cells administered at the site of HPV 16-induced neoplasms.
    Mendoza L; Bubeník J; Símová J; Korb J; Bieblová J; Vonka V; Indrová M; Mikysková R; Jandlová T
    Folia Biol (Praha); 2002; 48(3):114-9. PubMed ID: 12118725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
    Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
    Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines.
    Reinis M; Stepanek I; Simova J; Bieblova J; Pribylova H; Indrova M; Bubenik J
    Int J Oncol; 2010 Mar; 36(3):545-51. PubMed ID: 20126973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
    Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V
    Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.